<DOC>
	<DOC>NCT00932893</DOC>
	<brief_summary>This is a Phase 3 trial comparing the safety and anti-tumor activity of PF-02341066 versus pemetrexed or docetaxel in patients with advanced non-small cell lung cancer with specific gene profile involving the ALK gene after failure of one previous chemotherapy regimen that included one platinum drug.</brief_summary>
	<brief_title>An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<mesh_term>Crizotinib</mesh_term>
	<criteria>histologically or cytologically proven diagnosis of nonsmall cell lung cancer positive for the ALK fusion gene (test provided by a central laboratory) must have had disease progression after only one prior chemotherapy and that regimen but must have included one platinum drug tumors must be measurable prior treatment with PF02341066 current treatment in another clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Lung Neoplasms ALK gene crizotinib</keyword>
</DOC>